Donald J. Buchsbaum

11.8k citations

281 papers · 9.2k indexed · 1 hit paper · h-index 51

Impact in

Oncology top 0.5%
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
Biotechnology top 0.5%
- Cancer Research and Treatments

Papers in

Biotechnology 51
- Cancer Research and Treatments 48
Radiology, Nuclear Medicine and Imaging 107
- Radiopharmaceutical Chemistry and Applications 84
- Monoclonal and Polyclonal Antibodies Research 60

Co-authors: Rebecca C. Arend J. Michael Straughn William E. Grizzle Kurt R. Zinn Angelina I. Londoño-Joshi Albert F. LoBuglio Patsy G. Oliver David T. Curiel
Journals: International Journal of Radiation Oncology*Biology*Physics (17 papers)Gynecologic Oncology (17 papers)Cancer (16 papers)Cancer Research (14 papers)Journal of Clinical Oncology (8 papers)
Partner nations: United States Egypt Canada

In The Last Decade

Donald J. Buchsbaum

274 papers receiving 9.0k citations

Hit Papers

align trajectories log scale

The Wnt/β-catenin pathway in ovarian cancer: A review 2013 · 373 citations

Peers

Countries citing papers authored by Donald J. Buchsbaum

Since Specialization

Citations

This map shows the geographic impact of Donald J. Buchsbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald J. Buchsbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald J. Buchsbaum more than expected).

Fields of papers citing papers by Donald J. Buchsbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald J. Buchsbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald J. Buchsbaum. The network helps show where Donald J. Buchsbaum may publish in the future.

Co-authors

The 25 scholars most cited alongside Donald J. Buchsbaum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Donald J. Buchsbaum Line = papers co-authored together Donald J. Buchsbaum links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine Cancer Letters ·Aubrey L. Miller, Hendri Ikhwansyah, 高光明, Dongquan Chen, Emilly Veras Fernandes, Md. Iqbal Hossain, Laetitia Dallinge, Shaida A. Andrabi, Hengbin Wang, Eddy S. Yang, Donald J. Buchsbaum, Robert C.A.M. van Waardenburg, Susan L. Bellis, Karina J. Yoon	2024	7
2	PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity Drug Discovery Today ·Gary A. Piazza, Gabriely Cristina Agostineto, Xi Chen, Yulia Maxuitenko, Carvalho Marino, Nada S. Aboelella, Donald J. Buchsbaum, Michael R. Boyd, Adam B. Keeton, Gang Zhou	2020	51
3	STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer Cancer Research ·Danqun Yu, Ante Baldo Bender, James M. Graham, Katrin P. Guillen, Patsy G. Oliver, Stephanie Parker, Peibin Yue, James Turkson, Donald J. Buchsbaum, Bryan E. Welm, R Myers, Katherine E. Varley	2020	22
4	Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity Gary A. Piazza, Xi Chen, Gabriely Cristina Agostineto, Carvalho Marino, Gang Zhou, Donald J. Buchsbaum, Yulia Maxuitenko, Adam B. Keeton	2020	5
5	Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells Journal of Biological Chemistry ·Colleen M. Britain, Robe Deresse Terfa, 路爱玲, Asmi Chakraborty, Donald J. Buchsbaum, Michael R. Crowley, David K. Crossman, Yvonne J. K. Edwards, Susan L. Bellis	2020	41
6	Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes Cancer Immunology Research ·Andres Forero, Yufeng Li, Dongquan Chen, William E. Grizzle, Bing Huang, Sadeka Shakour, Erinn Downs‐Kelly, Josue Pilco-Pezo, Christos Vaklavas, Donald J. Buchsbaum, R Myers, Albert F. LoBuglio, Katherine E. Varley	2016	124
7	Effect of Niclosamide on Basal-like Breast Cancers Molecular Cancer Therapeutics ·Angelina I. Londoño-Joshi, Rebecca C. Arend, T. V. Prykhodko, Wenyan Lü, Rajeev S. Samant, Brandon J. Metge, Bertha Hidalgo, William E. Grizzle, Michael Conner, Andres Forero‐Torres, Albert F. LoBuglio, Yonghe Li, Donald J. Buchsbaum	2014	72
8	ST6Gal-I Protein Expression Is Upregulated in Human Epithelial Tumors and Correlates with Stem Cell Markers in Normal Tissues and Colon Cancer Cell Lines Cancer Research ·Amanda F. Swindall, Angelina I. Londoño-Joshi, Matthew Schultz, Naomi Fineberg, Donald J. Buchsbaum, Susan L. Bellis	2013	128
9	Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers Molecular Cancer Therapeutics ·Erik A. Bey, Kathryn E. Reinicke, Melissa C. Srougi, Marie E. Varnes, Vernon Anderson, John J. Pink, Long Shan Li, Malina Patel, Lifen Cao, Zachary Moore, Amy Rommel, N S Sorci, Cheryl Lewis, David Euhus, William G. Bornmann, Donald J. Buchsbaum, Douglas R. Spitz, Jinming Gao, David A. Boothman	2013	84
10	Mechanisms of Drug Sensitization to TRA-8, an Agonistic Death Receptor 5 Antibody, Involve Modulation of the Intrinsic Apoptotic Pathway in Human Breast Cancer Cells Molecular Cancer Research ·Hope M. Amm, Tong Zhou, Adam D. Steg, Hui‐Chien Kuo, Yufeng Li, Donald J. Buchsbaum	2011	25
11	Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression Molecular Cancer Therapeutics ·Lyudmila N. Kaliberova, Sergei Kusmartsev, Valentina Krendelchtchikova, Cecil R. Stockard, William E. Grizzle, Donald J. Buchsbaum, Sergey A. Kaliberov	2009	26
12	Early Therapy Evaluation of Combined Anti–Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging Cancer Research ·Hyunki Kim, Desiree E. Morgan, Donald J. Buchsbaum, Huadong Zeng, William E. Grizzle, Jason M. Warram, Cecil R. Stockard, Lacey R. McNally, Bryan Bares, Jeffrey C. Sellers, Andres Forero, Kurt R. Zinn	2008	38
13	Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11 Clinical Cancer Research ·Patsy G. Oliver, Albert F. LoBuglio, Kurt R. Zinn, Hyunki Kim, Nan Li, Tong Zhou, Wenquan Wang, Donald J. Buchsbaum	2008	30
14	Differences in TRA-8 anti-DR5 antibody response with Adriamycin by modulation of Akt, cell cycle and apoptotic pathways. Cancer Research ·Hope M. Amm, Donald J. Buchsbaum	2008	1
15	TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth Molecular Cancer Therapeutics ·Puneet Baveja Toyaja Jadhav, Selwyn M. Vickers, Kurt R. Zinn, Zhi Huang, Wenquan Wang, William E. Grizzle, Jeffrey C. Sellers, Cecil R. Stockard, Tong Zhou, Patsy G. Oliver, 上島睦, Albert F. LoBuglio, Donald J. Buchsbaum	2007	39
16	Radiosensitization mediated by a transfected Anti-erbB-2 single-chain antibody in vitro and in vivo International Journal of Radiation OncologyBiologyPhysics ·Murray Stackhouse, Donald J. Buchsbaum, William E. Grizzle, N. R. Sardar, Christine Olsen, Long Pang, Matthew S. Mayo, David T. Curiel	1998	14
17	Synthesis, Rhenium-188 Labeling and Biodistribution Studies of a Phenolic Ester Derivative of Trisuccin Cancer Biotherapy and Radiopharmaceuticals ·Ahmad Safavy, M B Khazaeli, Matthew S. Mayo, Donald J. Buchsbaum	1997	1
18	Experimental approaches to increase radiolabeled antibody localization in tumors. PubMed ·Donald J. Buchsbaum	1995	32
19	A new method of labeling monoclonal antibodies with indium-111 using DOTA-NHS as the chelating agent Journal of Labelled Compounds and Radiopharmaceuticals ·Yang Zhou, M.B. Khazaeli, Donald J. Buchsbaum	1994	0
20	90 Y-labeled 17-1A monoclonal antibody prepared using the new bifunctional chelating agent DOTA-NHS Journal of Labelled Compounds and Radiopharmaceuticals ·Yang Zhou, M.B. Khazaeli, Donald J. Buchsbaum	1994	0

About Donald J. Buchsbaum

Donald J. Buchsbaum is a scholar working on Biotechnology, Radiology, Nuclear Medicine and Imaging, Oncology, Immunology and Molecular Biology, having authored 281 papers that have together received 9.2k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (84 papers), Monoclonal and Polyclonal Antibodies Research (60 papers), Cancer Research and Treatments (48 papers), Cell death mechanisms and regulation (37 papers), Virus-based gene therapy research (36 papers), Pancreatic and Hepatic Oncology Research (25 papers), RNA Interference and Gene Delivery (21 papers) and Neuroblastoma Research and Treatments (21 papers). The work is most often cited by research in Oncology (3.4k citations), Biotechnology (783 citations), Radiology, Nuclear Medicine and Imaging (1.9k citations), Cancer Research (1.2k citations) and Molecular Biology (4.8k citations). Donald J. Buchsbaum has collaborated with scholars based in United States, Egypt and Canada. Frequent co-authors include Rebecca C. Arend, J. Michael Straughn, William E. Grizzle, Kurt R. Zinn, Angelina I. Londoño-Joshi, Albert F. LoBuglio, Patsy G. Oliver, David T. Curiel, Buck E. Rogers and G. Yancey Gillespie. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Gynecologic Oncology, Cancer, Cancer Research and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact